It seems that the Brits also want to use Avastin instead of Lucentis in treating AMD, and the UK’s cost-effectiveness body of NICE (the National Institute for Health and Clinical Excellence) is taking the first steps to appraise the off-label use of Avastin to replace the already approved use of Lucentis in AMD. As reported by Nick Smith of APM Health Europe, it appears that Lucentis’ high cost is beginning to effect the UK’s NHS and thus a look at the lower-cost anti-VEGF version, Avastin.
(I have written about the Brits (and others in Europe) wanting to use Avastin in (Read more...)